Materials and methods for inhibiting tumor growth
The subject invention provides compositions and methods for inhibiting the growth and/or proliferation of cancer cells. The subject invention also provides methods for treating cancer in a subject in need of such treatment by administering a composition described herein. The subject invention can be used to inhibit cancer cell growth by exposing the cells to a composition. The subject invention further provides cancer treatments that may be used in combination with surgery, chemotherapy, and/or radiation therapy.
1. A formulation for inhibiting proliferation of cancer cells comprising:
a therapeutically effective amount of free amino acids, the free amino acids consisting essentially of or consisting of free amino acids of:
proline, serine, threonine, tyrosine, and valine; or
proline, serine, threonine, tyrosine, valine, asparagine, and glycine; and
optionally a pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, or excipient;
wherein a therapeutically effective amount of the formulation inhibits proliferation of cancer cells.
2. The formulation of claim 1 , wherein the formulation does not comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof; or
when the formulation does comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof, the free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof are present in negligible amounts.
3. The formulation of claim 1 , wherein the cancer cells express anoctamin (ANO), wherein the ANO is anoctamin-1 (ANO-1).
4. A method of treating cancer expressing anoctamin (ANO) in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a formulation comprising:
a therapeutically effective amount of free amino acids, the free amino acids consisting essentially of or consisting of free amino acids of:
proline serine, threonine, tyrosine, and valine; or
proline, serine, threonine, tyrosine, valine, asparagine, and glycine; and
optionally a pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, or excipient;
wherein the cancer expressing ANO comprises cancer cells and a therapeutically effective amount of the formulation inhibits proliferation of the cancer cells.
5. The method of claim 4 , wherein the formulation does not comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof, or
when the formulation does comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof, the free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine are present in negligible amounts.
6. The method of claim 4 , wherein the ANO is anoctamin-1 (ANO-1).
7. The method of claim 4 , wherein the cancer comprises nasopharyngeal carcinoma, breast cancer, lung cancer, colon cancer, esophageal cancer, or bladder cancer.
8. A method of inhibiting cancer cell proliferation comprising exposing cancer cells expressing anoctamin (ANO) to a formulation comprising:
an effective amount of free amino acids, the free amino acids consisting essentially of or consisting of free amino acids of:
proline, serine, threonine, tyrosine, and valine; or
proline, serine, threonine, tyrosine, valine, asparagine, and glycine; and
optionally a pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, or excipient;
wherein the effective amount of the free amino acids inhibits proliferation of the cancer cells expressing ANO.
9. The method of claim 8 , wherein the formulation does not comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof; or
when the formulation does comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof, the free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine are present in negligible amounts.
10. A method of downregulating anoctamin (ANO) expression in at least one cancer cell, the method comprising contacting the at least one cancer cell with an effective amount of a formulation of claim 1 ,
wherein the therapeutically effective amount of the free amino acids downregulates ANO expression in the at least one cancer cell.
11. The method of claim 10 , wherein the formulation does not comprise free amino acids of glutamate, glutamine, aspartic acid, alanine, or isoleucine, or any combination thereof.
12. The method of claim 10 , wherein the anoctamin is ANO1.